BioCentury

Current Editions

November 30, 2021
ImmunoGen ADC hits mark in ovarian cancer subgroup, heads for FDA

Following 2019 miss in Phase III trial, ImmunoGen’s mirvetuximab finds success in narrower population

Product Development

Discovery & Translation

Regulation

FDA cancels ODAC meeting on two accelerated approvals

Decision may be last stop on regulatory ride for Farydak and Marqibo 

Nov. 30 Quick Takes: BeiGene’s $3.5B hat trick

Plus FDA panel narrowly backs molnupiravir and updates from Mana, Molecular Partners, Krystal, Mereo, Blueprint, AZ

Management Tracks

Pfizer’s Dormitzer to head GSK’s vaccine R&D

Phil Dormitzer is leaving Pfizer, where he has been scientific lead for development of the Comirnaty COVID-19 vaccine

Grauer becomes CMO at Federation Bio

Plus: LabGenius, 23andMe, Vifor, Immunovia, Forma and more

BioCentury ISSN 1097-7201